Notice: This company has been marked as potentially delisted and may not be actively trading. Ocuphire Pharma (OCUP) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Opus Genetics reinstated with a Buy at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comOpus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deThe RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 25, 2024 | prnewswire.comOcuphire Pharma Merges with Opus Genetics, Renamed Opus GeneticsOctober 24, 2024 | finance.yahoo.comOcuphire and Opus Genetics merge to develop IRD gene therapyOctober 24, 2024 | finance.yahoo.comOcuphire Pharma price target lowered to $10 from $18 at CanaccordOctober 24, 2024 | markets.businessinsider.comOcuphire Pharma Announces Acquisition of Opus GeneticsOctober 22, 2024 | globenewswire.comOcuphire Reports Positive Data For Phase 3 Trial Of Ryzumvi In Induced MydriasisSeptember 30, 2024 | markets.businessinsider.comOcuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologySeptember 30, 2024 | globenewswire.comUPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaSeptember 5, 2024 | globenewswire.comOcuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaSeptember 5, 2024 | stockhouse.comOcuphire Pharma Inc (R3X1.BE)September 3, 2024 | nz.finance.yahoo.comOcuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 16, 2024 | finance.yahoo.comR3X1.SG,0P0001L2U0,0 (R3X1.SG)August 9, 2024 | uk.finance.yahoo.comOcuphire Pharma to Present at Two Investor Conferences in AugustAugust 8, 2024 | globenewswire.comFuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsightAugust 2, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn SituationAugust 1, 2024 | finance.yahoo.comOcuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in JulyJuly 10, 2024 | globenewswire.comOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in JuneJune 6, 2024 | globenewswire.comBuy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline ProgressMay 13, 2024 | markets.businessinsider.comOcuphire Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 12, 2024 | finance.yahoo.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | investorplace.comOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 10, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingMay 6, 2024 | globenewswire.comOcuphire Pharma to Present at the Aegis Virtual ConferenceMay 3, 2024 | globenewswire.comOcuphire Pharma, Inc. (OCUP)April 24, 2024 | finance.yahoo.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingApril 22, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 11, 2024 | globenewswire.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | markets.businessinsider.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Pharma COO acquires $4.1k in company stockMarch 27, 2024 | investing.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri Buys 10,000 SharesMarch 26, 2024 | insidertrades.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath Buys 25,000 SharesMarch 21, 2024 | insidertrades.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023March 15, 2024 | investorplace.comEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their ForecastsMarch 13, 2024 | finance.yahoo.comBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy TreatmentMarch 11, 2024 | markets.businessinsider.comOcuphire Pharma Full Year 2023 Earnings: Misses ExpectationsMarch 10, 2024 | finance.yahoo.comOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateMarch 8, 2024 | globenewswire.comOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?March 4, 2024 | msn.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | investorplace.comOcuphire Pharma to Present in the BIO CEO & Investor ConferenceFebruary 23, 2024 | globenewswire.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | globenewswire.comOcuphire Pharma Inc (OCUP)February 15, 2024 | uk.investing.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | finance.yahoo.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 ConferenceFebruary 5, 2024 | finance.yahoo.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 24, 2024 | finance.yahoo.comOcuphire Pharma files for a $175M mixed securities shelfJanuary 10, 2024 | msn.com Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. OCUP Media Mentions By Week OCUP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUP News Sentiment▼0.000.87▲Average Medical News Sentiment OCUP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUP Articles This Week▼01▲OCUP Articles Average Week Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Context Therapeutics News Journey Medical News Pyxis Oncology News MediciNova News Monopar Therapeutics News Alto Neuroscience News Leap Therapeutics News Rani Therapeutics News Coya Therapeutics News Assembly Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUP) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
